Indian custom fine chemical contract manufacturing organizations (CMO) are no longer satisfied with increasing their share of the pharmaceutical intermediates market and have started to target the high-value, high-tech active pharma ingredient (API) sector, which until now was served only by European and North American competitors including BASF, Cambrex, and Degussa. Indian firms such as...

Read the full article